Amy represents life sciences and technology companies in a broad range of commercial transactions involving intellectual property.

Amy has over 10 years of experience advising early stage to Fortune 100 companies, including as a partner at an Am Law 100 firm, where she counseled clients on IP strategies and commercialization, patent opinions and portfolio management, and provided advice on legal and regulatory issues associated with drug and medical device development. In addition to her law firm experience, Amy has worked as an analyst at a premier service provider to the alternative assets industry and as a solo practitioner.

During law school, Amy was the associate editor of the Georgetown Law Journal.